NanoMedSyn offers a bioengineering platform using AMFA glycovectors targeting the mannose 6-phosphate receptor to create first-in-class drugs. These AMFA vectors are grafted onto therapeutic antibodies, enzymes or nanoparticles to allow their cellular internalisation and routing to lysosomes. NanoMedSyn will be the partner for the AMFA-coupling and characterisation of your new drug.
NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.
is the engineering of recombinant proteins like antibodies or enzymes for better therapies.
NanoMedSyn develops engineered therapeutics in-house and in partnership.